Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III study – AstraZeneca

by
  1. Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III studyAstraZeneca
  2. AstraZeneca drug does not extend lives of breast cancer patientsFinancial Times
  3. AstraZeneca, Daiichi suffer new setback with mixed results from breast cancer drugsBloomberg
  4. AstraZeneca, competitor to Daiichi’s Trodelvy, fails to improve overall survival in breast cancer trialFierce biotechnology
  5. AstraZeneca’s experimental drug disappoints in breast cancer survival studyCompany standard

Leave a Comment